ASNB - I'm expecting substantially increased product sales, and a return to profitably this year. I've always felt the key to ASNB's success lies here:
"ADVANSOURCE BIOMATERIALS ANNOUNCES MULTI-MILLION DOLLAR AGREEMENT WITH ACCESS SCIENTIFIC"
http://www.businesswire.com/news/home/20110426005794/en/Access-Scientific-AdvanSource-Biomaterials-Announce-Agreement-ChronoFlex
That agreement plus ASNB's financial trend (and some other results from my dredging of the internet) is what got me interested in the company. But it's been a bumpy road for Access Scientific over the last few years. I believe now, finally, Access Scientific's revolutionary "Powerwand" catheter will begin selling and sales will snowball over time. Clinical results are outstanding. Using ASNB's patented antimicrobial coating, the Powerwand will save lives and money. This is a result at just one hospital:
"Contrast these outcomes with the predictable consequences our patients would have had if PICCs had been mandated for all vancomycin administrations. At the low end of the reported PICC-associated bloodstream infection rate, approximately 16 patients in our cohort would have had catheter-associated bloodstream infections, and 1 or 2 of these patients quite possibly would have died. The unreimbursable cost of treating 16 patients with CLABSI would have been $896,000.23 Compare this with the actual hard-cost savings of $97,740 (1086 patients × $90 savings per procedure) that resulted from using the study midline catheter (the Powerwand) instead of a PICC for vancomycin administration."
http://www.avajournal.com/article/S1552-8855(16)30127-1/fulltext
I did very well when the increased product sales resulted in profits and a nice spike in the process. I do believe the increased product sales were for Chronoflex C to Access Scientific. I also believe that ASNB's Executive VP for Commercial Operations, who's been with them for many years, bought over $40,000 worth of shares on the open market (at .14) expecting the increased sales to continue. But the sales did not continue, filings later said there were "anticipated reductions" from one customer. I believe that customer was Access Scientific encountering more bumps on their road to marketing the Powerwand. But I believe now that their road has smoothed out. The news below is from January with the deal effective 12/1/16. Latest financials from ASNB are as of 12/31/16 so there's no way any increased sales have shown up yet. ASNB also announced a deal with an Israeli company that started in December 2016. Next filing for ASNB will be the annual report due out in mid-July. That will have sales through 3/31/17. Then we'll see a quarterly in August with sales through 6/30/17. I do believe ASNB will be back on track by then. Here's the Access Scientific news from January. I'm re-accumulating a large position here.
January 25, 2017
Access Scientific, LLC, Awarded Intalere Choice®
Agreement for POWERWAND™ Line of Catheters
SAN DIEGO – Access Scientific, a privately held medical device manufacturer of
the “evidence based, best in class” POWERWAND catheters, was awarded an
agreement with Intalere as a supplier of its valued Intalere Choice program.
Intalere is a leading group purchasing and total cost management organization
that serves 3,716 acute care facilities nationwide along with 37,356 clinics and
11,598 long term care facilities. For premium products, Intralere offers Intalere
Choice to provide their members the highest quality medical products in growing
sectors such as vascular access. The agreement became effective Dec. 1, 2016.
The agreement provides Intalere Choice member facilities access to Access
Scientific’s proprietary line of POWERWAND catheters, which have demonstrated
unparalleled performance in clinical outcomes:
3Fr, 4Fr and 5Fr (16Ga, 17Ga and 19Ga) catheter offering
Reduce overall central lines and central line days
12,000 catheter-days with no bloodstream infection
Highest flow rates
Excellent blood drawability
Cost savings (clinical and material)
The POWERWAND line of catheters has been proven to help facilities reduce
central line days and CLABSIs while improving quality care at a lower cost, all of
which are core to value-based purchasing.
“The Access team looks forward to partnering with Intalere and their members to
improve patient care and lower the overall cost of care through implementation
of our evidence-based Powerwand products and processes,” said Phil Royston,
President of Access Scientific.
About Access Scientific, LLC
Access Scientific is dedicated to the development and commercialization of
breakthrough, proprietary devices that make vascular access safer for patients
and reduce the cost of care. The company pioneered the power-injectable midline
market with the POWERWAND™. Made of proprietary ChronoFlex™ C, the
POWERWAND midline has been the proven, evidence based, best-in-class, with
over 12,000 catheter-days of published scientific data attesting to the lowest
complication rate and highest completion-of-therapy rate of any vascular access
device ever studied. The POWERWAND offers a unique approach to reducing
hospital-acquired infections. Visit www.accessscientific.com to learn more.
– END –
A more recent study shows 20,000 days of results.
"March 14, 2017
New Study Pushes POWERWAND Midline IV Catheter
to Over 20,000 Catheter Days with Zero BSIs"
http://3g033q44pk4o4eo9td3bwjsx.wpengine.netdna-cdn.com/wp-content/uploads/20000-Catheter-Days.pdf
News 
Market Data 
Discover 
AI
